The subject invention relates to a novel hepatitis B surface antigen
mutant and methods of detecting this mutant, and/or antibodies thereto,
in patient samples. In particular, the mutant contains a substitution of
amino acid threonine for the amino acid alanine at position 123 in the
amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.